• 1. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 2. Distinctive size effects of Pt nanoparticles immobilized on Fe3O4@PPy used as an efficient recyclable catalyst for benzylic alcohol aerobic oxidation and hydrogenation reduction of nitroaromatics
  Yu Long,Bing Yuan,Jianrui Niu,Xin Tong,Jiantai Ma New J. Chem., 2015,39, 1179-1185
• 3. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 4. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 5. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrans Xanthones
• Natural Products and Extracts Plant Extracts Plant based Frasera speciosa
• Xanthones
• Solvents and Organic Chemicals Organic Compounds Heterocyclic Compounds
• Solvents and Organic Chemicals Organic Compounds Aldehyde/Ketone

Chemical Profile of 9H-Xanthen-9-one, 1,7-dihydroxy-2,3-dimethoxy- (CAS No. 78405-33-1) and Its Emerging Applications in Modern Research

The compound 9H-Xanthen-9-one, 1,7-dihydroxy-2,3-dimethoxy-, identified by its CAS number 78405-33-1, represents a structurally intriguing heterocyclic molecule with significant potential in pharmaceutical and biochemical research. This xanthone derivative, characterized by its hydroxyl and methoxy substituents, has garnered attention due to its unique chemical properties and promising biological activities. The molecular framework of this compound encompasses a xanthene core, which is a well-studied scaffold in medicinal chemistry, known for its versatility in drug design.

In recent years, the exploration of xanthone derivatives has expanded considerably, driven by their demonstrated efficacy in various biological assays. The presence of multiple hydroxyl groups at the 1 and 7 positions, along with methoxy groups at the 2 and 3 positions, contributes to the compound's solubility and reactivity, making it a valuable candidate for further chemical manipulation and functionalization. These structural features not only enhance its interactions with biological targets but also facilitate its incorporation into complex synthetic pathways.

One of the most compelling aspects of 9H-Xanthen-9-one, 1,7-dihydroxy-2,3-dimethoxy- is its potential as an intermediate in the synthesis of more complex pharmacophores. Researchers have leveraged its scaffold to develop novel molecules with enhanced bioactivity. For instance, modifications of this core structure have led to compounds exhibiting anti-inflammatory, antioxidant, and anticancer properties. The hydroxyl and methoxy groups serve as versatile handles for further derivatization, enabling chemists to tailor the molecule's properties for specific applications.

The biological activity of this compound has been a focal point in recent studies. Preliminary research suggests that it may interfere with key cellular pathways involved in cancer progression. Specifically, its ability to modulate enzyme activity and protein-protein interactions has been investigated in vitro. These findings align with broader trends in oncology research, where natural product derivatives are being repurposed or redesigned to improve therapeutic outcomes. The structural motifs present in 9H-Xanthen-9-one, 1,7-dihydroxy-2,3-dimethoxy- are reminiscent of other xanthones that have shown promise in clinical trials.

Furthermore, the compound's interaction with biological systems has been explored through computational modeling studies. These simulations have provided insights into how the molecule binds to target proteins and enzymes. Such computational approaches are increasingly integral to drug discovery pipelines, as they allow researchers to predict binding affinities and optimize molecular structures before experimental validation. The results from these models suggest that 9H-Xanthen-9-one, 1,7-dihydroxy-2,3-dimethoxy- could be a potent inhibitor of certain kinases implicated in tumor growth.

The synthesis of this compound has also been refined over time. Advances in organic chemistry have enabled more efficient and scalable production methods. Techniques such as catalytic hydrogenation and selective oxidation have been employed to introduce the necessary functional groups while maintaining regioselectivity. This progress is crucial for translating laboratory discoveries into viable therapeutic agents. The availability of high-purity 9H-Xanthen-9-one, 1,7-dihydroxy-2,3-dimethoxy- (CAS No. 78405-33-1) from reputable suppliers ensures that researchers can conduct rigorous experiments without compromising on quality.

In conclusion,9H-Xanthen-9-one, 1,7-dihydroxy-2,3-dimethoxy- represents a structurally rich and biologically relevant compound with significant potential in pharmaceutical research. Its unique combination of hydroxyl and methoxy substituents makes it an attractive scaffold for drug development. As our understanding of molecular interactions continues to evolve,this xanthone derivative is poised to play a crucial role in advancing therapeutic strategies across multiple disease areas.

• 162473-22-5(9H-Xanthen-9-one,1,4,5-trihydroxy-)
• 1214-20-6(9H-Xanthen-9-one,2-methoxy-)
• 3722-51-8(Sieber Linker)
• 1818-28-6(2,4,5-Trimethoxyacetophenone)
• 1214-24-0(3,6-Dihydroxy-9H-xanthen-9-one)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)